StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report published on Saturday. The firm issued a sell rating on the biotechnology company's stock.
Genocea Biosciences Price Performance
Shares of Genocea Biosciences stock opened at $0.01 on Friday. The firm has a market cap of $557,385.66, a price-to-earnings ratio of -0.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 52-week low of $0.01 and a 52-week high of $2.16. The stock has a 50-day simple moving average of $0.01 and a 200-day simple moving average of $0.34.
Get Genocea Biosciences alerts:Institutional Investors Weigh In On Genocea Biosciences
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC bought a new position in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 9.31% of the company's stock.
About Genocea Biosciences
(Get Rating)Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.